These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32071169)

  • 1. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
    Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
    Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer.
    Tyagi K; Roy A; Mandal S
    Mol Biol Rep; 2024 Sep; 51(1):983. PubMed ID: 39276277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
    Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
    Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
    Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
    Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined MEK and BCL-2/X
    Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
    Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target.
    Kurimchak AM; Kumar V; Herrera-Montávez C; Johnson KJ; Srivastava N; Davarajan K; Peri S; Cai KQ; Mantia-Smaldone GM; Duncan JS
    Mol Cell Proteomics; 2020 Dec; 19(12):2068-2090. PubMed ID: 32994315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
    Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
    Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance.
    Marolt N; Pavlič R; Kreft T; Gjogorska M; Rižner TL
    Biomed Pharmacother; 2024 Aug; 177():117069. PubMed ID: 38968802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
    Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
    Hardy LR; Pergande MR; Esparza K; Heath KN; Önyüksel H; Cologna SM; Burdette JE
    Oncogene; 2019 Aug; 38(32):6003-6016. PubMed ID: 31296958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.
    Yu YL; Diao NN; Li YZ; Meng XH; Jiao WL; Feng JB; Liu ZP; Lu N
    Biochem Biophys Res Commun; 2018 Jun; 501(2):380-386. PubMed ID: 29709478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds.
    Taylor SJ; Hollis RL; Gourley C; Herrington CS; Langdon SP; Arends MJ
    Exp Mol Pathol; 2024 Aug; 138():104916. PubMed ID: 38959632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
    Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
    Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
    Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma.
    Sanders BE; Yamamoto TM; McMellen A; Woodruff ER; Berning A; Post MD; Bitler BG
    Mol Cancer Ther; 2022 Aug; 21(8):1285-1295. PubMed ID: 35587258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression.
    Sawyer BT; Qamar L; Yamamoto TM; McMellen A; Watson ZL; Richer JK; Behbakht K; Schlaepfer IR; Bitler BG
    Mol Cancer Res; 2020 Jul; 18(7):1088-1098. PubMed ID: 32198139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.